US Broker Ratings

Arbutus Biopharma (ABUS) Stock Analysis: Exploring a Potential 54% Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS), headquartered in Warminster, Pennsylvania, is making waves in the healthcare sector with its innovative approach to treating infectious diseases. Specializing in biotechnology, Arbutus is at..

Immunome, Inc. (IMNM) Stock Analysis: A Biotech Play with 173.74% Potential Upside

Investors with a keen eye on the biotechnology sector might find Immunome, Inc. (NASDAQ: IMNM) an intriguing prospect. With a market capitalization of $778.76 million, this U.S.-based clinical-stage biotech company..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Unveiling a Substantial 187.96% Upside Potential in Biotechnology

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a rising star in the biotechnology sector, offers investors an intriguing opportunity with its clinical-stage therapeutics targeting severe autoimmune and inflammatory diseases. Founded in 2019..

AnaptysBio, Inc. (ANAB) Stock Analysis: Investors Eyeing 82% Upside on Promising Biotech Innovations

AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology firm based in San Diego, California, is capturing investor attention with its innovative immunology therapeutics and a promising stock potential. With a market cap..

Beta Bionics, Inc. (BBNX) Stock Analysis: Exploring a 51% Potential Upside in the Medical Devices Sector

Beta Bionics, Inc. (NASDAQ: BBNX) is capturing investor interest with its promising potential upside of 51.37%, according to analyst ratings. Operating in the dynamic healthcare sector, this American medical devices..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Biotech Gem with 51% Potential Upside

LENZ Therapeutics, Inc. (NASDAQ: LENZ) is gaining attention in the biotechnology sector with its promising pipeline and impressive potential upside. As a company dedicated to improving vision through innovative therapies,..

Day One Biopharmaceuticals (DAWN) Stock Analysis: A 332% Potential Upside Opportunity in Biotech

Day One Biopharmaceuticals, Inc. (DAWN) is gaining attention in the biotech sector, with a compelling investment narrative supported by an impressive potential upside of 332.10%. Based in Brisbane, California, this..

iRadimed Corporation (IRMD) Stock Analysis: Exploring a 22.12% Upside Potential in the Healthcare Sector

iRadimed Corporation (NASDAQ: IRMD), a key player in the medical devices industry, is making waves with its promising potential upside of 22.12%. As it stands, the company’s market capitalization is..

GH Research PLC (GHRS) Stock Analysis: Unveiling a 185.60% Upside Potential for Biotech Investors

GH Research PLC (NASDAQ: GHRS) is making waves in the biotechnology sector with its promising pipeline of depression treatments and an impressive potential upside of 185.60%. Based in Dublin, Ireland,..

Niagen Bioscience (NAGE) Stock Analysis: A Promising Biotech with 8.32% Upside Potential

Niagen Bioscience, Inc. (NASDAQ: NAGE), a burgeoning name in the biotechnology sector, presents a compelling narrative for investors seeking exposure to the healthcare industry’s innovative edge. Founded in 1999 and..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Exploring a 245% Potential Upside in Biotech Innovation

Bicara Therapeutics Inc. (NASDAQ: BCAX) is capturing investor attention with its striking potential upside of 245.34%, as reflected by its average target price of $32.60 against the current trading price..

Pharming Group N.V. (PHAR) Stock Analysis: A Biotech Gem with 186% Upside Potential

Pharming Group N.V. (PHAR), a prominent player in the biotechnology sector, is capturing investor attention with its impressive potential for upside. With a current market capitalization of $724.97 million, the..

Trevi Therapeutics, Inc. (TRVI) Stock Analysis: Exploring a 224.95% Potential Upside in Biotech

For investors eyeing the healthcare sector, particularly the dynamic field of biotechnology, Trevi Therapeutics, Inc. (NASDAQ: TRVI) presents an intriguing opportunity. With a market capitalization of $647.1 million and a..

Praxis Precision Medicines (PRAX) Stock Analysis: A 154% Potential Upside with Analyst Confidence

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a cutting-edge player in the biotechnology sector, is capturing investor attention with its promising clinical advancements and a remarkable 154% potential upside, according to..

CareDx, Inc. (CDNA) Stock Analysis: Exploring a 76.85% Potential Upside in the Diagnostics Sector

For investors keen on tapping into the healthcare sector’s diagnostics and research industry, CareDx, Inc. (NASDAQ: CDNA) offers an intriguing proposition. With its focus on developing cutting-edge diagnostic solutions for..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: A Biotech Gem with 111% Potential Upside

Investors seeking promising opportunities in the biotechnology sector might find Gyre Therapeutics, Inc. (NASDAQ: GYRE) an intriguing prospect. With its focus on developing innovative small-molecule drugs targeting inflammation and fibrosis,..

HealthStream, Inc. (HSTM) Stock Analysis: Exploring a 23.70% Upside Potential in Healthcare SaaS

HealthStream, Inc. (NASDAQ: HSTM) is a noteworthy player in the health information services industry, providing Software-as-a-Service (SaaS) solutions tailored for healthcare organizations across the United States. With a market capitalization..

CorMedix Inc. (CRMD)

⚠️ No article content returned.

..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Navigating Potential Downside Amidst Robust Revenue Growth

Phibro Animal Health Corporation (NASDAQ: PAHC) stands as a key player in the healthcare sector, specializing in the development and distribution of products that enhance animal health and nutrition. With..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: A 196% Potential Upside Amid Clinical Innovations

Arcus Biosciences, Inc. (NASDAQ: RCUS) presents a compelling case for investors, particularly those drawn to the high-risk, high-reward nature of the biotechnology sector. With its focus on developing groundbreaking cancer..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds